SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (鈥淔LAMES Study鈥? NCT04169997) investigating the poly (ADP-ribose) polymerase (鈥淧ARP鈥? inhibitor, senaparib (product code: JS109/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (鈥淚MPACT Therapeutics鈥?, as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (鈥淔IGO鈥? stage III/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the 鈥淚DMC鈥? concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed